146 related articles for article (PubMed ID: 11396214)
21. Free and total serum PSA values in patients with prostatic intraepithelial neoplasia (PIN), prostate cancer and BPH. Is F/T PSA a potential probe for dormant and manifest cancer?
Tarle M; Kraljić I
Anticancer Res; 1997; 17(3A):1531-4. PubMed ID: 9179191
[TBL] [Abstract][Full Text] [Related]
22. Limited usefulness of the free-to-total prostate-specific antigen ratio for the diagnosis and staging of prostate cancer in Japanese men.
Sakai I; Harada K; Hara I; Eto H; Miyake H
Int J Clin Oncol; 2004 Feb; 9(1):64-7. PubMed ID: 15162829
[TBL] [Abstract][Full Text] [Related]
23. [Comparative value of molecular forms of prostate-specific antigen in diagnosis of prostatic cancer].
Mazo EB; Sergeeva NA; Grigor'ev ME; Lebedev DV; Solov'eva EV; Konorev VA; Krovets AA
Urologiia; 2006; (3):21-4. PubMed ID: 16889084
[TBL] [Abstract][Full Text] [Related]
24. Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease.
Berruti A; Mosca A; Tucci M; Terrone C; Torta M; Tarabuzzi R; Russo L; Cracco C; Bollito E; Scarpa RM; Angeli A; Dogliotti L
Endocr Relat Cancer; 2005 Mar; 12(1):109-17. PubMed ID: 15788643
[TBL] [Abstract][Full Text] [Related]
25. Clinical understaging in patients with prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum chromogranin A.
Sciarra A; Voria G; Monti S; Mazzone L; Mariotti G; Pozza M; D'Eramo G; Silverio FD
Prostate; 2004 Mar; 58(4):421-8. PubMed ID: 14968443
[TBL] [Abstract][Full Text] [Related]
26. Free-to-total prostate specific antigen ratio in clinical staging of prostate cancer.
Maeda H; Arai Y; Ishitoya S; Okubo K; Aoki Y; Okada T; Maekawa S
Hinyokika Kiyo; 1998 May; 44(5):307-11. PubMed ID: 9656100
[TBL] [Abstract][Full Text] [Related]
27. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer.
Chun FK; Perrotte P; Briganti A; Benayoun S; Lebeau T; Ramirez A; Lewinshtein DJ; Valiquette L; Guay JP; Karakiewicz PI
BJU Int; 2006 Jul; 98(1):50-3. PubMed ID: 16831142
[TBL] [Abstract][Full Text] [Related]
28. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy.
Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS
Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093
[TBL] [Abstract][Full Text] [Related]
29. Detection of prostate cancer with complexed PSA and complexed/total PSA ratio - is there any advantage?
Strittmatter F; Stieber P; Nagel D; Füllhase C; Walther S; Stief CG; Waidelich R
Eur J Med Res; 2011 Oct; 16(10):445-50. PubMed ID: 22024423
[TBL] [Abstract][Full Text] [Related]
30. Percent free PSA as an additional measure in a prostate cancer screen.
Miele ME
Clin Lab Sci; 2001; 14(2):102-7. PubMed ID: 15625982
[TBL] [Abstract][Full Text] [Related]
31. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients.
Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T
Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374
[TBL] [Abstract][Full Text] [Related]
32. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
33. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer.
Chun FK; Hutterer GC; Perrotte P; Gallina A; Valiquette L; Benard F; McCormack M; Briganti A; Ionescu C; Jeldres C; Guay JP; Saad F; Karakiewicz PI
BJU Int; 2007 Jul; 100(1):37-41. PubMed ID: 17488305
[TBL] [Abstract][Full Text] [Related]
34. Prostatic specific antigen and bone scan in the diagnosis and follow-up of prostate cancer. Can diagnostic significance of PSA be increased?
Bantis A; Grammaticos P
Hell J Nucl Med; 2012; 15(3):241-6. PubMed ID: 23227460
[TBL] [Abstract][Full Text] [Related]
35. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
[TBL] [Abstract][Full Text] [Related]
36. [Usefulness of free PSA/total PSA ratio in the diagnosis of prostatic cancer in symptomatic patients with PSA levels ranging from 2.5 to 20 ng/ml].
Herranz Amo F; Verdú Tartajo F; Díez Cordero JM; Leal Hernández F; Bielsa Carrillo A; García Burgos J; Subirá Ríos D
Actas Urol Esp; 2000 Jan; 24(1):24-30. PubMed ID: 10746371
[TBL] [Abstract][Full Text] [Related]
37. Neuroendocrine differentiation in carcinomas of the prostate: do neuroendocrine serum markers reflect immunohistochemical findings?
Angelsen A; Syversen U; Haugen OA; Stridsberg M; Mjølnerød OK; Waldum HL
Prostate; 1997 Jan; 30(1):1-6. PubMed ID: 9018329
[TBL] [Abstract][Full Text] [Related]
38. The chromogranin-A (CgA) in prostate cancer.
Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M
Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP
BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903
[TBL] [Abstract][Full Text] [Related]
40. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]